RCP Diagnostics LLC
This article was originally published in Start Up
Executive Summary
The principal goal of RCP Diagnostics is to commercialize a blood-based diagnostic for estrogen-associated cancers in women. The assay, initially developed as a radioimmunoassay, detects the presence of a protein that ferries vitamin B-2, or riboflavin, throughout the body.
You may also be interested in...
Women's Health: A Growing Market for Diagnostic Players
Women's health is an area long shunned by pharmaceutical and diagnostic companies. But that is starting to change thanks to the successes of companies such as Cytyc and Digene, who have built successful testing franchises in the Ob/ Gyn market. As companies such as PerkinElmer and others look to develop new tests in this market, a spate of start-ups are developing technologies that might fit the bill. Of greatest interest are the so-called molecular tests since they offer the advantage of premium pricing.
Women's Health: A Growing Market for Diagnostic Players
Women's health is an area long shunned by pharmaceutical and diagnostic companies. But that is starting to change thanks to the successes of companies such as Cytyc and Digene, who have built successful testing franchises in the Ob/ Gyn market. As companies such as PerkinElmer and others look to develop new tests in this market, a spate of start-ups are developing technologies that might fit the bill. Of greatest interest are the so-called molecular tests since they offer the advantage of premium pricing.
GW Medical Technologies LLC
GW Medical Technologies' blood test for Alzheimer's is one of the few that doesn't attempt to directly measure amyloid beta. Instead, the company's diagnostic measures CD69 levels on peripheral blood lymphocytes. Two clinical trials of the test, developed at the University of Leipzig, have already been performed and the data suggest the diagnostic is 95% accurate.